Pacific Bio (NASDAQ: PACB) reported Q3 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $34.9 million versus the consensus estimate of $33.23 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.